Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, et al. J Clin Oncol 2025;43:15-21.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Galsky MD, Witjes JA, Gschwend JE, Milowsky MI, et al. Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. J Clin Oncol 2025;43:15-21.
PMID: 39393026